Senetek says trial shows PRK 124 reduces signs of aging, decreases redness in skin

By E. Janene Geiss

Philadelphia, June 13 - Senetek plc announced Tuesday successful results in its initial clinical trial of PRK 124, a new cytokinin anti-aging compound.

The study involved 30 female subjects over a 12-week period, according to a company news release.

Standard parameters were measured for establishing the safety and efficacy of skin anti-aging products. In addition to self-assessments, the subjects were examined at baseline and at two, four, eight and 12 weeks by expert clinical investigators, officials said.

Instrumentation used in the study included the NOVA Dermal Phase Meter for measuring the moisture content in the skin, TEWA meter for measuring transepidermal water loss, high resolution clinical photography and skin replicas, which measured improvement in fine lines and coarse wrinkles.

In addition to studying PRK 124's ability to ameliorate the signs of facial skin aging, its effect on reducing erythema (redness) also was studied in order to determine whether PRK 124 would be a candidate for further study in inflammatory skin conditions.

Both expert and subject assessments showed significant improvements in the various parameters measured beginning at two weeks, officials said.

The company said PRK 124 was highly effective in improving the texture of the skin, decreasing skin roughness, one of the most difficult to treat signs of skin aging.

PRK 124's effect on significantly reducing redness was seen as early as two weeks. PRK 124 also produced a significant decrease in transepidermal water loss, improvement in skin barrier integrity and a significant increase in skin moisture content, officials said.

It is noteworthy that PRK 124 was well-tolerated by all subjects.

"PRK 124 has the potential to be a franchise product in the dermatological and skincare marketplace, not only for ameliorating the signs of skin aging but with further testing, PRK 124 may be indicated for the treatment of inflammatory skin disorders, such as acne rosacea and psoriasis," Frank J. Massino, chairman and chief executive officer, said in the release.

Senetek is a Napa, Calif., life sciences-driven product development and licensing company focused on dermatological and skin care products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.